0001140215 2022-01-01 2022-03-31 0001140215 2022-05-11 0001140215 2022-03-31 0001140215 2021-12-31 0001140215 2021-01-01 2021-03-31 0001140215 us-gaap:CommonStockMember 2021-12-31 0001140215 us-gaap:PreferredStockMember 2021-12-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001140215 us-gaap:RetainedEarningsMember 2021-12-31 0001140215 us-gaap:CommonStockMember 2020-12-31 0001140215 us-gaap:PreferredStockMember 2020-12-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001140215 us-gaap:RetainedEarningsMember 2020-12-31 0001140215 2020-12-31 0001140215 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001140215 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001140215 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001140215 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001140215 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001140215 us-gaap:CommonStockMember 2022-03-31 0001140215 us-gaap:PreferredStockMember 2022-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001140215 us-gaap:RetainedEarningsMember 2022-03-31 0001140215 us-gaap:CommonStockMember 2021-03-31 0001140215 us-gaap:PreferredStockMember 2021-03-31 0001140215 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001140215 us-gaap:RetainedEarningsMember 2021-03-31 0001140215 2021-03-31 0001140215 REED:InstitutionalInvestorsMember REED:SecuredConvertibleNotesMember us-gaap:SubsequentEventMember 2022-05-09 0001140215 REED:InstitutionalInvestorsMember REED:SecuredConvertibleNotesMember us-gaap:SubsequentEventMember 2022-05-08 2022-05-09 0001140215 REED:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:VendorOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:VendorOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:VendorTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-03-31 0001140215 REED:VendorOneMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-03-31 0001140215 REED:NoVendorMember us-gaap:AccountsPayableMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001140215 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001140215 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001140215 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001140215 REED:UnvestedRestrictedCommonStockMember 2022-01-01 2022-03-31 0001140215 REED:UnvestedRestrictedCommonStockMember 2021-01-01 2021-03-31 0001140215 REED:SeriesAConvertiblePreferredStockMember 2022-01-01 2022-03-31 0001140215 REED:SeriesAConvertiblePreferredStockMember 2021-01-01 2021-03-31 0001140215 REED:RightOfUseAssetsUnderOperatingLeasesMember 2022-03-31 0001140215 REED:RightOfUseAssetsUnderOperatingLeasesMember 2021-12-31 0001140215 REED:ComputerHardwareAndSoftwareMember 2022-03-31 0001140215 REED:ComputerHardwareAndSoftwareMember 2021-12-31 0001140215 us-gaap:MachineryAndEquipmentMember 2022-03-31 0001140215 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-31 0001140215 REED:AlternaCapitalSolutionsMember 2021-12-31 0001140215 REED:RosenthalAndRosenthalIncMember 2022-03-31 0001140215 REED:RosenthalAndRosenthalIncMember 2021-12-31 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-27 2022-03-28 0001140215 REED:AlternaCapitalSolutionsMember 2022-03-28 0001140215 REED:AlternaCapitalSolutionsMember 2022-01-01 2022-03-31 0001140215 REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-12-31 0001140215 REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 srt:MinimumMember REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 srt:MaximumMember REED:FinancingAgreementMember REED:RosenthalAndRosenthalIncMember 2018-01-01 2018-12-31 0001140215 REED:RosenthalAgreementMember 2021-03-10 2021-03-11 0001140215 REED:JohnJBelloMember 2022-03-31 0001140215 REED:JohnJBelloMember 2022-01-01 2022-03-31 0001140215 us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-09 2022-03-10 0001140215 us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-10 0001140215 REED:OfficersAndDirectorsMember us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-10 0001140215 REED:OfficerAndDirectorsMember us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-10 0001140215 REED:OfficerAndDirectorsMember us-gaap:PrivatePlacementMember REED:SecuritiesPurchaseAgreementMember 2022-03-09 2022-03-10 0001140215 REED:JohnJBelloAndNancyEBelloMember 2022-01-01 2022-01-31 0001140215 srt:MinimumMember REED:JohnJBelloAndNancyEBelloMember 2022-01-31 0001140215 us-gaap:RestrictedStockMember 2021-12-31 0001140215 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001140215 us-gaap:RestrictedStockMember 2022-03-31 0001140215 REED:NonEmployeeDirectorsMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember REED:FebruaryOneTwoThousandTwentyOneMember us-gaap:RestrictedStockMember 2021-01-25 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember REED:MayOneTwoThousandTwentyTwoAugustOneTwoThousandTwentyTwoAndNovemberOneTwoThousandTwentyTwoMember us-gaap:RestrictedStockMember 2021-01-26 0001140215 REED:FiveNonEmployeeDirectorsMember us-gaap:RestrictedStockMember 2021-01-26 0001140215 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001140215 REED:TwoThousandTwentyIncentiveCompensationPlanMember 2022-03-31 0001140215 REED:EmployeesMember 2022-01-01 2022-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001140215 us-gaap:EmployeeStockOptionMember 2022-03-31 0001140215 us-gaap:StockOptionMember 2021-12-31 0001140215 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001140215 us-gaap:StockOptionMember 2022-03-31 0001140215 REED:StockWarrantsMember 2022-03-31 0001140215 REED:JohnBelloMember REED:SatisfactionSettlementAndReleaseAgreementMember 2021-11-24 0001140215 2021-11-23 2021-11-24 0001140215 REED:JohnBelloMember REED:SatisfactionSettlementAndReleaseAgreementMember 2021-12-31 0001140215 REED:JohnBelloMember REED:SatisfactionSettlementAndReleaseAgreementMember 2022-01-01 2022-03-31 0001140215 us-gaap:WarrantMember 2021-12-31 0001140215 us-gaap:WarrantMember 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2018-12-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2022-01-01 2022-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2019-12-31 0001140215 us-gaap:RoyaltyMember REED:CaliforniaCustomBeverageLLCMember 2022-01-01 2022-03-31 0001140215 us-gaap:RoyaltyMember REED:CaliforniaCustomBeverageLLCMember 2021-01-01 2021-03-31 0001140215 REED:ChrisReedMember REED:CaliforniaCustomBeverageLLCMember 2021-12-31 0001140215 us-gaap:RoyaltyMember 2022-01-01 2022-03-31 0001140215 REED:LindsayMartinMember srt:VicePresidentMember 2022-01-01 2022-03-31 0001140215 REED:LindsayMartinMember srt:VicePresidentMember 2021-01-01 2021-03-31 0001140215 us-gaap:SubsequentEventMember 2022-04-01 2022-05-16 0001140215 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember REED:NotePurchaseAgreementMember 2022-05-09 0001140215 us-gaap:SubsequentEventMember us-gaap:PrivatePlacementMember REED:NotePurchaseAgreementMember 2022-05-08 2022-05-09 iso4217:USD shares iso4217:USD shares pure REED:Segment 0001140215 false Q1 --12-31

P4Y

10-Q true 2022-03-31 2022 false 001-32501 REED’S, INC. DE 35-2177773 201 Merritt 7 Norwalk CT 06851 (800) 997-3337 Common Stock REED NASDAQ 112652320 Yes Yes Non-accelerated Filer true false false

122000

49000

277000

234000

5161000

5183000

20848000

17049000

1135000

933000

1561000

1491000

28827000

24705000

613000

561000

940000

992000

624000

30391000

26321000

16359000

10434000

689000

286000

470000 0

7475000

10229000

735000

614000

167000

161000

25425000

21724000

350000

394000

25775000

22118000

500000

9411

94000

0.0001

180000000

112551890

93733975

11000

9000

112628000

107237000

-108117000

-103137000

4616000

4203000

30391000

26321000

12182000

12146000

9250000

8293000

2932000

3853000

2812000 3286000

2178000

2215000

2121000

2603000

7111000

8104000

-4179000

-4251000

801000

256000

-4980000

-4507000

-0.05

97377408

86631304

93733975

9000

9411

94000

107237000

-103137000

4203000

225000 225000

136594

66000

13250

2000

100000

37000

18594571

2000

5065000

5067000

-4980000

112551890

11000

9411

94000

112628000

-108117000

4616000

86317096

9000

9411

94000

97031000

-86730000

10404000

300000 300000

84809

98000

6000

3000

400000

472000

-4507000

86807905

9000

9411

94000

97904000

-91237000

6770000

-4980000

-4507000

25000

32000

65000

162000

431000

25000

-225000 -292000 -66000 -106000 -37000

62000

-69000

10000

-20000

3000

40000

244000

3810000

1306000

617000

484000

27000 24000

5926000

1387000

403000

-446000

-37000

-8000

-2207000

-5059000

2000

95000

-97000

14508000

16154000

17212000

11898000

5067000

2000

-81000

459000

-2000

3000

2280000

4716000

73000

-440000

49000

595000

122000

155000

256000

70000

1. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed financial statements of Reed’s, Inc. (the “Company”, “we”, “us”, or “our”), have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on April 15, 2022. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the three months ended March 31, 2022 and 2021. The balance sheet as of December 31, 2021 is derived from the Company’s audited financial statements. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended March 31, 2022, the Company recorded a net loss of $4,980 and used cash in operations of $2,207. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2021, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. As of March 31, 2022, we had a cash balance of $122, with no current availability, and $5,100 of additional borrowing capacity, stockholders’ equity of $4,616 and a working capital of $3,402. On May 9, 2022 the Company issued $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zCtyiEHAwFk7" title="Debt instrument, face amount">11,250 of secured convertible notes to certain institutional investors. The convertible notes mature <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zd1ky5W1Omwh" title="Debt instrument, maturity date">May 9, 2025, bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zUE8TdTf8DBb" title="Debt instrument, interest rate">10% per annum, and are secured by substantially all of the Company’s assets. The initial conversion rate of the convertible notes is <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_z5KcoUvGEak" title="Debt instrument, conversion price">4.1503 shares of the Company’s common stock per one dollar of principal amount converted (See Note 11). Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. To alleviate these conditions, management is currently evaluating various funding alternatives and may seek to raise additional funds through the issuance of equity, mezzanine or debt securities, through arrangements with strategic partners or through obtaining credit from financial institutions. As we seek additional sources of financing, there can be no assurance that such financing would be available to us on favorable terms or at all. Our ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, our performance and investor sentiment with respect to us and our industry. We have also taken decisive action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating improved vendor contracts and restructuring our selling prices. During the first quarter of 2022, the Company continued to strengthen its supply chain, implement gross margin enhancement initiatives, drive efficiencies in transportation and warehouse costs and reduce operating expenses. The Company remains focused on driving sales growth and improving margin. The sales growth focus is on channel expansion, new product introduction and improved sales execution. The margin enhancement initiative is driven by co-packer upgrades, better leveraged purchasing and improved efficiency. Underpinning these initiatives is a focus on strategically reducing operating costs, particularly delivery and handling expenses. During 2021, the Company experienced elevated transportation costs over the prior year and anticipates these costs to remain elevated for the balance of 2022. Plans have been implemented to mitigate the impact of these costs. COVID-19 Considerations During the period ended March 31, 2022, the COVID-19 pandemic continued to impact our operating results and the Company anticipates a residual effect for the balance of the year. In addition, the pandemic could cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products, we believe that over the long term, there will continue to be strong demand for our products. Through March 31, 2022, the Company was able to lower its freight costs despite a higher transportation market as the capacity in the freight market has not kept up with demand. The Company believes these challenges will continue throughout the year. In addition, the Company experienced increases in the pricing of several of its raw materials and delays in procuring several of these items. However, mitigation plans have been implemented to manage this risk. Additionally, the Company was negatively impacted by supply chain challenges impacting our ability to benefit from strong demand for, and increased sales of our product. The disruption caused by labor shortages, significant raw material cost inflation, logistics issues and increased freight costs, and ongoing port congestion, resulted in suppressed margins and net income. The Company anticipates a continued impact throughout 2022. Our ability to operate without significant incremental negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and protect our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the inception of the COVID-19 pandemic and through March 31, 2022, we maintained the consistency of our operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating with our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers and suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations. We have not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfilment activity rather than a promised service to the customer. All of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. The Company does not allow for returns, except for damaged products when the damage occurred pre-fulfilment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis. Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the periods ended March 31, 2022 and 2021, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zics3NFSIFVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Potentially Dilutive Securities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220331_zXfWyJpRX173" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20210331_zuQrfSsWkb3j" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLEFWmPtA8Nj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,835,768</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,362,241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zaj24578KhVi" style="vertical-align: bottom; background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,145,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,028,322</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_z3a2J0YmlJ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested restricted common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,082</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zUwHNELC1Fyg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Series A Convertible Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zesfHRZRrXZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">24,394,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,737,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Stock Compensation Expense The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods. Advertising Costs Advertising costs are expensed as incurred and are included in selling and marketing expense. Advertising costs aggregated $312 and $349 for the three months ended March 31, 2022 and 2021, respectively. Concentrations Net sales. During the three months ended March 31, 2022, the Company’s two largest customers accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZY0CsLKbLf7">18% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zk0hsczfRifd">12% of net sales, respectively. During the three months ended March 31, 2021, the Company’s two largest customers accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZyrZ2FKXuG9">23% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTfg1Gobm7kk">12% of net sales, respectively. No other customers exceeded 10% of net sales in either period. Accounts receivable. As of March 31, 2022, the Company had accounts receivable from one customer which comprised <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHKhwsESXQTa" title="Concentration risk, percentage">23% of its gross accounts receivable. As of December 31, 2021, the Company had accounts receivable from one customer which comprised <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zjk1TnujLBkb" title="Concentration risk, percentage">18% of its gross accounts receivable. No other customers exceeded 10% of gross accounts receivable in either period. Purchases from vendors. During the three months ended March 31, 2022, the Company’s largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD31KimJVbAl" title="Percentage of sale accounted to customer">13% of all purchases. During the three months ended March 31, 2021, the Company’s two largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYwb5CUfVlf" title="Concentration Risk, Percentage">13% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyA5GBpWBlD6" title="Concentration Risk, Percentage">13% of all purchases, respectively. No other vendors exceeded 10% of all purchases in either period. Accounts payable. As of March 31, 2022, the Company’s two largest vendors accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYYcDjlRh5H5">11% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgMYzlFPSTg3">10% of the total accounts payable, respectively. As of December 31, 2021, no vendor accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--NoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zh8jPLmUFVq5" title="Concentration risk, percentage">10% the total accounts payable. No other vendors exceeded 10% of gross accounts payable in either period. Fair Value of Financial Instruments The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. ASC 820 defines the following levels of subjectivity associated with the inputs: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, short-term bank loans, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of capital lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06 “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”).” ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective January 1, 2024, for the Company and the provisions of this update can be adopted using either the modified retrospective method or a fully retrospective method. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Effective January 1, 2021, the Company early adopted ASU 2020-06 and that adoption did not have an impact on our financial statements and related disclosures. In May 2021, the FASB issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s financial statement presentation or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Basis of Presentation The accompanying condensed financial statements of Reed’s, Inc. (the “Company”, “we”, “us”, or “our”), have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on April 15, 2022. The accompanying condensed financial statements are unaudited, but in the opinion of management contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2022, and the results of its operations and its cash flows for the three months ended March 31, 2022 and 2021. The balance sheet as of December 31, 2021 is derived from the Company’s audited financial statements. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022.

Going Concern The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the three months ended March 31, 2022, the Company recorded a net loss of $4,980 and used cash in operations of $2,207. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2021, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. As of March 31, 2022, we had a cash balance of $122, with no current availability, and $5,100 of additional borrowing capacity, stockholders’ equity of $4,616 and a working capital of $3,402. On May 9, 2022 the Company issued $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zCtyiEHAwFk7" title="Debt instrument, face amount">11,250 of secured convertible notes to certain institutional investors. The convertible notes mature <span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zd1ky5W1Omwh" title="Debt instrument, maturity date">May 9, 2025, bear interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_zUE8TdTf8DBb" title="Debt instrument, interest rate">10% per annum, and are secured by substantially all of the Company’s assets. The initial conversion rate of the convertible notes is <span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SecuredConvertibleNotesMember__srt--TitleOfIndividualAxis__custom--InstitutionalInvestorsMember_z5KcoUvGEak" title="Debt instrument, conversion price">4.1503 shares of the Company’s common stock per one dollar of principal amount converted (See Note 11). Historically, we have financed our operations through public and private sales of common stock, issuance of preferred and common stock, convertible debt instruments, term loans and credit lines from financial institutions, and cash generated from operations. To alleviate these conditions, management is currently evaluating various funding alternatives and may seek to raise additional funds through the issuance of equity, mezzanine or debt securities, through arrangements with strategic partners or through obtaining credit from financial institutions. As we seek additional sources of financing, there can be no assurance that such financing would be available to us on favorable terms or at all. Our ability to obtain additional financing in the debt and equity capital markets is subject to several factors, including market and economic conditions, our performance and investor sentiment with respect to us and our industry. We have also taken decisive action to improve our margins, including fully outsourcing our manufacturing process, streamlining our product portfolio, negotiating improved vendor contracts and restructuring our selling prices. During the first quarter of 2022, the Company continued to strengthen its supply chain, implement gross margin enhancement initiatives, drive efficiencies in transportation and warehouse costs and reduce operating expenses. The Company remains focused on driving sales growth and improving margin. The sales growth focus is on channel expansion, new product introduction and improved sales execution. The margin enhancement initiative is driven by co-packer upgrades, better leveraged purchasing and improved efficiency. Underpinning these initiatives is a focus on strategically reducing operating costs, particularly delivery and handling expenses. During 2021, the Company experienced elevated transportation costs over the prior year and anticipates these costs to remain elevated for the balance of 2022. Plans have been implemented to mitigate the impact of these costs.

-4980000

-2207000

122000

5100000

4616000

3402000

11250

2025-05-09

0.10

4.1503

COVID-19 Considerations During the period ended March 31, 2022, the COVID-19 pandemic continued to impact our operating results and the Company anticipates a residual effect for the balance of the year. In addition, the pandemic could cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products. Based on the recent increase in demand for our products, we believe that over the long term, there will continue to be strong demand for our products. Through March 31, 2022, the Company was able to lower its freight costs despite a higher transportation market as the capacity in the freight market has not kept up with demand. The Company believes these challenges will continue throughout the year. In addition, the Company experienced increases in the pricing of several of its raw materials and delays in procuring several of these items. However, mitigation plans have been implemented to manage this risk. Additionally, the Company was negatively impacted by supply chain challenges impacting our ability to benefit from strong demand for, and increased sales of our product. The disruption caused by labor shortages, significant raw material cost inflation, logistics issues and increased freight costs, and ongoing port congestion, resulted in suppressed margins and net income. The Company anticipates a continued impact throughout 2022. Our ability to operate without significant incremental negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and protect our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the inception of the COVID-19 pandemic and through March 31, 2022, we maintained the consistency of our operations during the onset of the COVID-19 pandemic. We will continue to innovate in managing our business, coordinating with our employees and suppliers to do our part in the infection prevention and remain flexible in responding to our customers and suppliers. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations. We have not observed any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic.

Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfilment activity rather than a promised service to the customer. All of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. The Company does not allow for returns, except for damaged products when the damage occurred pre-fulfilment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

Loss per Common Share Basic earnings (loss) per share is computed by dividing the net income (loss) applicable to common stockholders by the weighted average number of shares of common stock outstanding during the year, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings (loss) per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. For the periods ended March 31, 2022 and 2021, the calculations of basic and diluted loss per share are the same because potential dilutive securities would have had an anti-dilutive effect. The potentially dilutive securities consisted of the following: <p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zics3NFSIFVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Potentially Dilutive Securities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220331_zXfWyJpRX173" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20210331_zuQrfSsWkb3j" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLEFWmPtA8Nj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,835,768</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,362,241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zaj24578KhVi" style="vertical-align: bottom; background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,145,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,028,322</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_z3a2J0YmlJ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested restricted common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,082</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zUwHNELC1Fyg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Series A Convertible Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zesfHRZRrXZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">24,394,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,737,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zics3NFSIFVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Potentially Dilutive Securities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20220101__20220331_zXfWyJpRX173" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20210331_zuQrfSsWkb3j" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLEFWmPtA8Nj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">13,835,768</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,362,241</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zaj24578KhVi" style="vertical-align: bottom; background-color: White"> <td>Options</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,145,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,028,322</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedRestrictedCommonStockMember_z3a2J0YmlJ5k" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unvested restricted common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">309,082</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeriesAConvertiblePreferredStockMember_zUwHNELC1Fyg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Series A Convertible Preferred stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37,644</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zesfHRZRrXZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">24,394,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">14,737,289</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

13835768

3362241

10145176

11028322

376290

309082

37644

24394878

14737289

Stock Compensation Expense The Company periodically issues stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for such grants issued and vesting based on ASC 718, Compensation-Stock Compensation whereby the value of the award is measured on the date of grant and recognized for employees as compensation expense on the straight-line basis over the vesting period. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. The fair value of the Company’s stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Advertising Costs Advertising costs are expensed as incurred and are included in selling and marketing expense. Advertising costs aggregated $312 and $349 for the three months ended March 31, 2022 and 2021, respectively.

312000

349000

Concentrations Net sales. During the three months ended March 31, 2022, the Company’s two largest customers accounted for <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZY0CsLKbLf7">18% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zk0hsczfRifd">12% of net sales, respectively. During the three months ended March 31, 2021, the Company’s two largest customers accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zZyrZ2FKXuG9">23% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zTfg1Gobm7kk">12% of net sales, respectively. No other customers exceeded 10% of net sales in either period. Accounts receivable. As of March 31, 2022, the Company had accounts receivable from one customer which comprised <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHKhwsESXQTa" title="Concentration risk, percentage">23% of its gross accounts receivable. As of December 31, 2021, the Company had accounts receivable from one customer which comprised <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zjk1TnujLBkb" title="Concentration risk, percentage">18% of its gross accounts receivable. No other customers exceeded 10% of gross accounts receivable in either period. Purchases from vendors. During the three months ended March 31, 2022, the Company’s largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zD31KimJVbAl" title="Percentage of sale accounted to customer">13% of all purchases. During the three months ended March 31, 2021, the Company’s two largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20210101__20210331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYwb5CUfVlf" title="Concentration Risk, Percentage">13% and <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zyA5GBpWBlD6" title="Concentration Risk, Percentage">13% of all purchases, respectively. No other vendors exceeded 10% of all purchases in either period. Accounts payable. As of March 31, 2022, the Company’s two largest vendors accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYYcDjlRh5H5">11% and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgMYzlFPSTg3">10% of the total accounts payable, respectively. As of December 31, 2021, no vendor accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--NoVendorMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zh8jPLmUFVq5" title="Concentration risk, percentage">10% the total accounts payable. No other vendors exceeded 10% of gross accounts payable in either period.

0.18

0.12

0.23

0.12

0.23

0.18

0.13

0.11

0.10

Fair Value of Financial Instruments The Company uses various inputs in determining the fair value of its financial assets and liabilities and measures these assets on a recurring basis. Financial assets recorded at fair value are categorized by the level of subjectivity associated with the inputs used to measure their fair value. ASC 820 defines the following levels of subjectivity associated with the inputs: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3—Unobservable inputs based on the Company’s assumptions. The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable, short-term bank loans, accounts payable, notes payable and other payables, approximate their fair values because of the short maturity of these instruments. The carrying values of capital lease obligations and long-term financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.

Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-06 “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”).” ASU 2020-06 reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion and beneficial conversion models. The diluted net income per share calculation for convertible instruments will require the Company to use the if-converted method. For contracts in an entity’s own equity, the type of contracts primarily affected by this update are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement conditions of the derivative scope exception. This update simplifies the related settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective January 1, 2024, for the Company and the provisions of this update can be adopted using either the modified retrospective method or a fully retrospective method. Early adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year. Effective January 1, 2021, the Company early adopted ASU 2020-06 and that adoption did not have an impact on our financial statements and related disclosures. In May 2021, the FASB issued ASU 2021-04 “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. The Company adopted ASU 2021-04 effective January 1, 2022. The adoption of ASU 2021-04 did not have any impact on the Company’s financial statement presentation or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

2. Inventory Inventory is valued at the lower of cost (first-in, first-out) or net realizable value, net of write downs, and is comprised of the following (in thousands): Schedule of Inventory <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220331_zod0qPmGhPh2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zW4ZqP4mgFjh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz4dt_zSzOcAUGkEs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials and packaging</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,853</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,221</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz4dt_zCxXUkobDFpa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,828</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINz4dt_zwN1VonAaEc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,848</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Inventory is valued at the lower of cost (first-in, first-out) or net realizable value, net of write downs, and is comprised of the following (in thousands): Schedule of Inventory <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220331_zod0qPmGhPh2" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zW4ZqP4mgFjh" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINz4dt_zSzOcAUGkEs8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials and packaging</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,853</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">11,221</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINz4dt_zCxXUkobDFpa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished products</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,995</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,828</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINz4dt_zwN1VonAaEc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,848</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

11853000

11221000

8995000

5828000

20848000

17049000

3. Property and Equipment Property and equipment is comprised of the following (in thousands): Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220331_zojzUyO9coQj" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z6pOOpdeKZe4" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--RightOfUseAssetsUnderOperatingLeasesMember_zBFtftxNJ7c4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Right-of-use assets under operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">724</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">724</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_z9tdgdcVvfji" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer hardware and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z29EBkixxSe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Machinery and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzorg_zIHGeO3HnO9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzorg_zwadKjiTXkj8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzorg_zaNDjbm91RFg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">940</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Depreciation expense for the three months ended March 31, 2022 and 2021 was $25 and $32, respectively, and amortization of right-of-use assets for the three months ended March 31, 2022 and 2021 was $27 and $24, respectively.

Property and equipment is comprised of the following (in thousands): Schedule of Property and Equipment <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220331_zojzUyO9coQj" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20211231_z6pOOpdeKZe4" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--RightOfUseAssetsUnderOperatingLeasesMember_zBFtftxNJ7c4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Right-of-use assets under operating leases</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">724</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">724</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerHardwareAndSoftwareMember_z9tdgdcVvfji" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Computer hardware and software</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_z29EBkixxSe4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Machinery and equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">429</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzorg_zIHGeO3HnO9i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,553</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzorg_zwadKjiTXkj8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(613</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(561</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzorg_zaNDjbm91RFg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Net book value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">940</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">992</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

724000

400000

429000

1553000

613000

561000

940000

992000

25000

32000

27000

24000

4. Intangible Assets Intangible assets consist of the following (in thousands): Summary of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220331_zKFMwplZRbVk" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_z6sJJeHPU0s8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--IndefiniteLivedTradeNames_iI_pn3n3_maILIAEzdvn_zlq5kzIHgf46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Brand names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">576</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">576</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IndefiniteLivedTrademarks_iI_pn3n3_maILIAEzdvn_zVD7QsbMlsUe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iTI_pn3n3_mtILIAEzdvn_zNioJZl9yDn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

Intangible assets consist of the following (in thousands): Summary of Intangible Assets <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220331_zKFMwplZRbVk" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20211231_z6sJJeHPU0s8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--IndefiniteLivedTradeNames_iI_pn3n3_maILIAEzdvn_zlq5kzIHgf46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Brand names</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">576</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">576</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IndefiniteLivedTrademarks_iI_pn3n3_maILIAEzdvn_zVD7QsbMlsUe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Trademarks</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iTI_pn3n3_mtILIAEzdvn_zNioJZl9yDn3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">624</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

576000

48000

624000

5. Line of Credit Amounts outstanding under the Company’s credit facilities are as follows (in thousands): Schedule of Amount Outstanding Under Credit Facilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: italic"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220331_zHMO7onjhli1" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zp0BCn3ItBIi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_z33l1pRFTCW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Line of credit – Alterna Capital Solutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--RosenthalAndRosenthalIncMember_zRKyzdZQLYu5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Line of credit – Rosenthal & Rosenthal</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">10,229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--RosenthalAndRosenthalIncMember_zapFshI1rZP9" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left; padding-bottom: 1.5pt">Total</td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt; text-align: right">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt; text-align: right">10,229</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zgF75RGYwfFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Capitalized financing costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(470</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_zrRaHWLSZ8Vj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,229</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Alterna Capital Solutions On March 28, 2022, the Company entered into a financing agreement with Alterna Capital Solutions (“ACS”), for a line of credit to replace its existing credit facility. The ACS line of credit is for a term of 3 years, provides for borrowings of up to $<span id="xdx_904_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220328__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_ze05A08SVnW3" title="Line of credit facility, maximum borrowing capacity">13,000, and is secured by eligible accounts receivable and inventory. An over advance rider provides for up to $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220327__20220328__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_zWvEpq4nm5C4" title="Line of credit facility, maximum amount outstanding during period">400 of additional borrowing beyond those amounts (the “Over Advance”). At March 31, 2022, no unused borrowing capacity was available under the financing agreement. <span id="xdx_901_eus-gaap--LineOfCreditFacilityInterestRateDescription_c20220327__20220328__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_zBItv7q0weeb" title="Line of credit facility, interest rate description">Borrowings based on receivables bears an interest of prime plus 4.75% but not less than 8.0%. Borrowings based on inventory bears an interest of prime plus 5.25% but not less than 8.5%. The additional over advance rider bears a rate of prime plus 12.75%, but not less than 16.00%. Additionally, the line of credit is subject to monthly monitoring fee of $1 with a minimum usage requirement on the credit facility. A loan balance of less than $1,500 will bear interest at a rate in line with account receivables advances plus the monthly monitoring fee of $1. The Company incurred $503 of direct costs of the transaction, consisting primarily of broker, bank and legal fees. These costs have been capitalized and are being amortized over the <span id="xdx_909_ecustom--AmortizationOfLineOfCreditPeriod_dtY_c20220327__20220328__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_zlAZyvOMUmVf" title="Amortization of line of credit period">3-year life of the ACS agreement. For the three months ended March 31, 2022, amortization of debt discount was $<span id="xdx_90D_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20220101__20220331__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_zsBKr9p0C2i4" title="Amortization of debt discount">33, and as of March 31, 2022, the remaining unamortized debt discount balance is $<span id="xdx_90B_ecustom--DebtInstrumentRemainingUnamortizedDiscount_iI_pn3n3_c20220331__us-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_zl0T3r4d8xr7" title="Remaining unamortized debt discount amount">470. Rosenthal & Rosenthal (paid off in full on March 30, 2022) In 2018, the Company entered into a financing agreement with Rosenthal & Rosenthal, Inc. (“Rosenthal”) that provided a maximum borrowing capacity of $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20181231__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_zZJGXtWn0Ht8" title="Line of credit facility, maximum borrowing capacity">13,000, based on eligible accounts receivable and inventories (the “permitted borrowings”) plus advances (an “over-advance” of up to $<span id="xdx_904_ecustom--LineOfCreditFacilityExcessOfPermittedBorrwingAmount_iI_pn3n3_c20181231__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_zhfewWdAijjc" title="Line of credit facility excess of permitted borrwing mount">4,000) in excess of permitted borrowings. On March 30, 2022, the Company paid in full the outstanding balance on its credit facility with Rosenthal with proceeds from ACS discussed above. Borrowings under the Rosenthal financing agreement bore interest at the greater of prime or <span id="xdx_90D_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_zplSV7dNxXCe" title="Line of credit, interest rate">4.75%, plus an additional <span id="xdx_906_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20180101__20181231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_zn4HCnFb51B1" title="Line of credit, interest rate">2.0% to <span id="xdx_906_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20180101__20181231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_znoAL9szK6f5" title="Line of credit, interest rate">3.5% depending on whether the borrowing was based upon receivables, inventory or is an over-advance. Additionally, the Rosenthal line of credit was subject to monthly facility and administration fees, and aggregate minimum monthly fees (including interest) of $<span id="xdx_900_ecustom--MinimumMonthlyFees_pn3n3_c20180101__20181231__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__dei--LegalEntityAxis__custom--RosenthalAndRosenthalIncMember_z8O0Ckw2Q0i8" title="Minimum monthly fees">4. The line of credit was secured by substantially all of the assets, excluding intellectual property, of the Company. The over-advance was secured by all of Reed’s intellectual property collateral. On March 11, 2021, the Company entered into an amendment to the Rosenthal agreement and replaced a standby letter of credit of $1,500 by a guarantor with a $2,000 pledge of securities to Rosenthal by John J. Bello and Nancy E. Bello, as Co-Trustees of The John and Nancy Bello Revocable Living Trust. John J. Bello, current Chairman and former Interim Chief Executive Officer of Reed’s, is a related party, and greater than <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20220331__srt--TitleOfIndividualAxis__custom--JohnJBelloMember_zlVPbqkhq2Ga" title="Equity method investment, ownership percentage">5% beneficial owner of Reed’s common stock. As consideration for the collateral support, Mr. Bello received <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--JohnJBelloMember_zx56Am0UW2g2" title="Number of restricted stock issued">400,000 shares of Reed’s restricted stock, with a fair value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn3n3_c20220101__20220331__srt--TitleOfIndividualAxis__custom--JohnJBelloMember_zKzeXLfHj34j" title="Fair value of restricted stock issued">472 which was recorded a prepaid financing cost. During the three months ended March 31, 2022, $121 of the prepaid financing cost was amortized, and as of March 31, 2022, there was no remaining unamortized prepaid finance cost balance. The Company annually incurs an additional $130 of fees from the bank, which is equal to 1% of the $13,000 borrowing limit. Amortization of this debt discount was $65 and $162 for the three months ended March 31, 2022, and 2021, respectively. At March 31, 2022, there was no remaining unamortized debt discount balance.

Amounts outstanding under the Company’s credit facilities are as follows (in thousands): Schedule of Amount Outstanding Under Credit Facilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: italic"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20220331_zHMO7onjhli1" style="border-bottom: Black 1.5pt solid; text-align: center">March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20211231_zp0BCn3ItBIi" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_409_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--AlternaCapitalSolutionsMember_z33l1pRFTCW4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Line of credit – Alterna Capital Solutions</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">7,945</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--RosenthalAndRosenthalIncMember_zRKyzdZQLYu5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Line of credit – Rosenthal & Rosenthal</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">10,229</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--RosenthalAndRosenthalIncMember_zapFshI1rZP9" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left; padding-bottom: 1.5pt">Total</td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt; text-align: right">-</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt"> </td> <td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 1.5pt; text-align: right">10,229</td><td style="display: none; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredFinanceCostsNet_iNI_pn3n3_di_zgF75RGYwfFb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Capitalized financing costs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(470</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LinesOfCreditCurrent_iI_pn3n3_zrRaHWLSZ8Vj" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,475</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,229</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7945000

10229000

470000

7475000

10229000

P3Y

13000000

400000

Borrowings based on receivables bears an interest of prime plus 4.75% but not less than 8.0%. Borrowings based on inventory bears an interest of prime plus 5.25% but not less than 8.5%. The additional over advance rider bears a rate of prime plus 12.75%, but not less than 16.00%. Additionally, the line of credit is subject to monthly monitoring fee of $1 with a minimum usage requirement on the credit facility

1500000

1000

503000

P3Y

33000

470000

13000000

4000000

0.0475

0.020

0.035

4000

On March 11, 2021, the Company entered into an amendment to the Rosenthal agreement and replaced a standby letter of credit of $1,500 by a guarantor with a $2,000 pledge of securities to Rosenthal by John J. Bello and Nancy E. Bello, as Co-Trustees of The John and Nancy Bello Revocable Living Trust.

1500000

0.05

400000

472000

121000

130000

0.01

13000000

65000

162000

6. Leases Liabilities During the three months ended March 31, 2022 and 2021, lease costs totaled $27 and $24, respectively. As of December 31, 2021, operating lease liabilities totaled $555. During the three months ended March 31, 2022, the Company made payments of $38 towards its operating lease liability. As of March 31, 2022, operating lease liabilities totaled $518. As of March 31, 2022, the weighted average remaining lease terms for an operating lease are 2.76 years. As of March 31, 2022, the weighted average discount rate on the operating lease is 12.60%.

27000

24000

555000

38000

518000

P2Y9M3D

0.1260

7. Stockholder’s Equity On March 10, 2022, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the investors agreed to purchase <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220309__20220310__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHRqoUOvjUri">18,594,571 shares of the Company’s common stock and warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zJrIAsm7biQ">9,297,289 shares of common stock in a private placement (including <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--OfficersAndDirectorsMember_z6tlu8ZsfGCl">3,248,142 shares of the Company’s common stock and warrants to purchase 1,624,071 shares of common stock to investors who are officers and directors of the Company). The warrants have an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zp4wBwBj6Ye8">0.2877 per share for a period of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zoIxJfclYRUf">five years commencing six months from the closing date of March 11, 2022. The purchase price per share of common stock and associated warrant was $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zMrFWhAyKFoh">0.28 for certain investors and was $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20220310__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorsMember_zUHM8YenM6Mj">0.3502 for investors who are officers and directors of the Company in compliance with the rules of the Nasdaq Stock Market. The net proceeds to the Company, after deducting placement agent fees and other offering expenses, was approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20220309__20220310__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorsMember_zrdlrHDmMk0e">5.1 million. The officers and directors of the Company purchased approximately $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20220309__20220310__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--OfficerAndDirectorsMember_zvrNzMo0yXnf">1.1 million of the securities in the offering. In January 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnJBelloAndNancyEBelloMember_zKveCq6Dhrze" title="Number of shares issued, shares">100,000 shares of common stock valued at $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20220101__20220131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnJBelloAndNancyEBelloMember_zTCeZnmc4Cja" title="Number of shares issued, value">37 to John J. Bello and Nancy E. Bello, as Co-Trustees of The John and Nancy Bello Revocable Living Trust as consideration for the $<span id="xdx_90A_ecustom--PledgeOfSecurities_pn3n3_c20220101__20220131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnJBelloAndNancyEBelloMember_zRTG3a4hNCE4" title="Amount for pledge of securities">2,000 pledge of securities to Rosenthal (see Note 5). John J. Bello, current Chairman and former Interim Chief Executive Officer of Reed’s, is a related party, and greater than <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_c20220131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JohnJBelloAndNancyEBelloMember__srt--RangeAxis__srt--MinimumMember_zvvokXzWL1A4" title="Beneficial ownership percentage">5% beneficial owner of Reed’s common stock.

18594571

9297289

3248142

0.2877

P5Y

0.28

0.3502

5100000

1100000

100000

37000

2000000

0.05

8. Stock-Based Compensation Restricted common stock The following table summarizes restricted stock activity during the three months ended March 31, 2022: Summary of Non-vested Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value at Date of Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance, December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zj82TblKVAL1" style="width: 10%; text-align: right" title="Unvested Shares, beginning balance">111,164</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfIssuableShares_iS_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOy49jYYVqo5" style="width: 10%; text-align: right" title="Issuable Shares, beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedFairValue_iS_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaKt5OENBtKi" style="width: 10%; text-align: right" title="Fair value unvested, beginning balance">54</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzj1CCPVagub" style="width: 10%; text-align: right" title="Weighted average grant date fair value, unvested, beginning balance">0.89</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z692f5wi0v62" style="text-align: right" title="Unvested shares, granted">401,720</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIssuableSharesGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5ZgNFCg2ht8" style="text-align: right" title="Issuable shares, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGranted_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDih0E6rVoX4" style="text-align: right" title="Fair value, granted">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAYT80TX3FH1" style="text-align: right" title="Weighted average grant date fair value, granted">0.37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJYtLDilJffh" style="text-align: right" title="Unvested shares, vested">(136,594</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfIssuableShares_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYjn1mpwYR61" style="text-align: right" title="Issuable shares, vested">136,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgeL0Q57miTa" style="text-align: right" title="Fair value, vested">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaNpfjtOIfj8" style="text-align: right" title="Weighted average grant date fair value, vested">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNdJgpBux8y9" style="text-align: right" title="Unvested shares, forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEQZY4lXtzcd" style="text-align: right" title="Weighted average grant date fair value, forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOal2mj8COjk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested shares, issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfIssuableSharesIssued_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5bhe80KUSs1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuable shares, issued">(136,594</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIssued_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE0NQ7psJ9Sf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, issued">(66</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsIssuedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSdk17Lzl2S3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zX4DaJUFC825" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, ending balance">376,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfIssuableShares_iE_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHSX0jWdXafb" style="border-bottom: Black 2.5pt double; text-align: right" title="Issuable shares, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedFairValue_iE_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVlPoz6EuON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, unvested, ending balance">138</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdYhVzEJUMr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested, ending balance">0.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> On January 26, 2022, the board of directors of Reed’s, pursuant to a joint recommendation from its governance and compensation committees, set the cash compensation of its non-employee directors at $50,000 for fiscal 2021, payable quarterly in accordance with the company’s policies for non-employee director compensation. In addition, the Company granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_uShares_c20210125__20210126__srt--TitleOfIndividualAxis__custom--FiveNonEmployeeDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z34AMIS7Jc9k">401,720 restricted stock awards to five non-employee directors. <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_uShares_c20210125__20210126__srt--TitleOfIndividualAxis__custom--FiveNonEmployeeDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--AwardDateAxis__custom--FebruaryOneTwoThousandTwentyOneMember_zhUXBwS6Txv3">100,430 of these restricted stock awards vested on February1, 2022. The remaining <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_uShares_c20210126__srt--TitleOfIndividualAxis__custom--FiveNonEmployeeDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--AwardDateAxis__custom--MayOneTwoThousandTwentyTwoAugustOneTwoThousandTwentyTwoAndNovemberOneTwoThousandTwentyTwoMember_zpppzNpmHLug">301,290 restricted stock awards will vest equally on May 1, 2022, August 1, 2022, and November 1, 2022. The aggregate fair value of the stock awards was $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_pn3n3_c20210125__20210126__srt--TitleOfIndividualAxis__custom--FiveNonEmployeeDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdkB7wIkSUNb">150 based on the market price of our common stock price which was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20210126__srt--TitleOfIndividualAxis__custom--FiveNonEmployeeDirectorsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg22OQb71Lug">0.32 per share on the date of grants and is amortized as shares vest. The total fair value of restricted common stock vesting during the three months ended March 31, 2022 and 2021, was $66 and $98, respectively, and is included in general and administrative expenses in the accompanying statements of operations. As of March 31, 2022, the amount of unvested compensation related to issuances of restricted common stock was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXbXD5XCaFR3">138, which will be recognized as an expense in future periods as the shares vest. When calculating basic loss per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. Stock options The following table summarizes stock option activity during the three months ended March 31, 2022: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Remaining Contractual Terms (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdPYkhmtVtnc" style="width: 10%; text-align: right" title="Shares outstanding, beginning balance">10,522,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHzkxq25oPKk" style="width: 10%; text-align: right" title="Weighted-average exercise price, outstanding, beginning">1.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z00rCKamZst5" title="Weighted-average remaining contractual terms (Years), outstanding beginning">7.88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_uUSD_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6mMaUTwqQk9" style="width: 10%; text-align: right" title="Aggregate intrinsic value, shares outstanding, beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAhB8Jrk0Zt6" style="text-align: right" title="Stock option, granted">60,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GQopvLpLM9" style="text-align: right" title="Weighted-average exercise pice, granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjNq9PnZRDE3" style="text-align: right" title="Stock option, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBv5UQxHTt8a" style="text-align: right" title="Weighted-average exercise pice, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unvested forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlD24QcXcJWk" style="text-align: right" title="Stock option, unvested forfeited or expired">(236,818</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAnnXt8cWeV4" style="text-align: right" title="Weighted-average exercise pice, unvested forfeited or expired">1.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Vested forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zstifau9sdvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock option vested forfeited or expired">(201,001</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztPyo2ZBZBIf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-average exercise price, vested forfeited or expired">1.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHt19S9Z1ucf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares outstanding, ending balance">10,145,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhO9JQikixIk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-average exercise price, outstanding, ending">1.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcwVaeOcq4Od" title="Weighted-average remaining contractual terms (Years), outstanding ending">7.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLnYZgkOQ8Mj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, shares outstanding, ending">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVaJvYVRlxYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares exercisable">4,784,540</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGm9mFdGuIl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable ending balance">1.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAXoIT4wMCoi" title="Weighted-average remaining contractual terms (Years), outstanding excerisable">7.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCA2Jr4kXkma" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, shares outstanding, exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended March 31, 2022, the Company approved options exercisable into <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_uShares_c20220331__us-gaap--PlanNameAxis__custom--TwoThousandTwentyIncentiveCompensationPlanMember_zExC9cASFa12" title="Number of shares available for grant">60,000 shares to be issued pursuant to Reed’s 2020 Equity Incentive Plan. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331__srt--TitleOfIndividualAxis__custom--EmployeesMember_zHj52QeT443k">60,000 options were issued to employees, <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zDN29hw1Ncvl" title="Stock option vesting period annually">30,000 options vesting annually over a <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zg91JJ51UGs5" title="Stock option vesting period::XDX::P4Y">four-year vesting period, and <span id="xdx_908_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znQ7RHOsXEz4" title="Stock option, vested">30,000 options vesting based on performance criteria to be established by the board of directors. The stock options are exercisable at a price of $0.29 per share and expire in ten years. The total fair value of these options at grant date was approximately $12, which was determined using a Black-Scholes-Merton option pricing model with the following average assumption: stock price of $0.29 share, expected term of six years, volatility of 82%, dividend rate of 0%, and weighted average risk-free interest rate of 1.72%. The expected term represents the weighted-average period of time that share option awards granted are expected to be outstanding giving consideration to vesting schedules and historical participant exercise behavior; the expected volatility is based upon historical volatility of the Company’s common stock; the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the share option award. During the three months ended March 31, 2022 and 2021, the Company recognized $225 and $300 of compensation expense relating to vested stock options. As of March 31, 2022, the aggregate amount of unvested compensation related to stock options was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20220331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLByt1FDluG9" title="Aggregate value of unvested compensation">2,398 which will be recognized as an expense as the options vest in future periods through March 28, 2026. As of March 31, 2022, the outstanding and exercisable options have no intrinsic value. The aggregate intrinsic value was calculated as the difference between the closing market price as of March 31, 2022, which was $0.30, and the exercise price of the outstanding stock options.

The following table summarizes restricted stock activity during the three months ended March 31, 2022: Summary of Non-vested Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Unvested Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Issuable Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value at Date of Issuance</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Balance, December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zj82TblKVAL1" style="width: 10%; text-align: right" title="Unvested Shares, beginning balance">111,164</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfIssuableShares_iS_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOy49jYYVqo5" style="width: 10%; text-align: right" title="Issuable Shares, beginning balance">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedFairValue_iS_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaKt5OENBtKi" style="width: 10%; text-align: right" title="Fair value unvested, beginning balance">54</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzj1CCPVagub" style="width: 10%; text-align: right" title="Weighted average grant date fair value, unvested, beginning balance">0.89</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z692f5wi0v62" style="text-align: right" title="Unvested shares, granted">401,720</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIssuableSharesGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5ZgNFCg2ht8" style="text-align: right" title="Issuable shares, granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGranted_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zDih0E6rVoX4" style="text-align: right" title="Fair value, granted">150</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAYT80TX3FH1" style="text-align: right" title="Weighted average grant date fair value, granted">0.37</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_pid_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJYtLDilJffh" style="text-align: right" title="Unvested shares, vested">(136,594</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfIssuableShares_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYjn1mpwYR61" style="text-align: right" title="Issuable shares, vested">136,594</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgeL0Q57miTa" style="text-align: right" title="Fair value, vested">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaNpfjtOIfj8" style="text-align: right" title="Weighted average grant date fair value, vested">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_iN_pid_di_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNdJgpBux8y9" style="text-align: right" title="Unvested shares, forfeited">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEQZY4lXtzcd" style="text-align: right" title="Weighted average grant date fair value, forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOal2mj8COjk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Unvested shares, issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNumberOfIssuableSharesIssued_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z5bhe80KUSs1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Issuable shares, issued">(136,594</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIssued_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE0NQ7psJ9Sf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value, issued">(66</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsIssuedWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSdk17Lzl2S3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, issued">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zX4DaJUFC825" style="border-bottom: Black 2.5pt double; text-align: right" title="Unvested shares, ending balance">376,290</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfIssuableShares_iE_pid_uShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHSX0jWdXafb" style="border-bottom: Black 2.5pt double; text-align: right" title="Issuable shares, ending balance">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedFairValue_iE_pn3n3_uUSD_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVlPoz6EuON8" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value, unvested, ending balance">138</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zdYhVzEJUMr2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested, ending balance">0.51</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

111164

54000

0.89

401720 150000

0.37

136594

136594 -136594 -66000

376290

138000

0.51

50000000

401720

100430

301290

150000

0.32

66000

98000

138000

The following table summarizes stock option activity during the three months ended March 31, 2022: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted- Average Remaining Contractual Terms (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zdPYkhmtVtnc" style="width: 10%; text-align: right" title="Shares outstanding, beginning balance">10,522,995</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHzkxq25oPKk" style="width: 10%; text-align: right" title="Weighted-average exercise price, outstanding, beginning">1.12</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z00rCKamZst5" title="Weighted-average remaining contractual terms (Years), outstanding beginning">7.88</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_uUSD_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z6mMaUTwqQk9" style="width: 10%; text-align: right" title="Aggregate intrinsic value, shares outstanding, beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAhB8Jrk0Zt6" style="text-align: right" title="Stock option, granted">60,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_z9GQopvLpLM9" style="text-align: right" title="Weighted-average exercise pice, granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zjNq9PnZRDE3" style="text-align: right" title="Stock option, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zBv5UQxHTt8a" style="text-align: right" title="Weighted-average exercise pice, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unvested forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zlD24QcXcJWk" style="text-align: right" title="Stock option, unvested forfeited or expired">(236,818</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAnnXt8cWeV4" style="text-align: right" title="Weighted-average exercise pice, unvested forfeited or expired">1.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Vested forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zstifau9sdvg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock option vested forfeited or expired">(201,001</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_ztPyo2ZBZBIf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-average exercise price, vested forfeited or expired">1.61</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zHt19S9Z1ucf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares outstanding, ending balance">10,145,176</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zhO9JQikixIk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted-average exercise price, outstanding, ending">1.09</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zcwVaeOcq4Od" title="Weighted-average remaining contractual terms (Years), outstanding ending">7.82</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_uUSD_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zLnYZgkOQ8Mj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, shares outstanding, ending">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zVaJvYVRlxYk" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares exercisable">4,784,540</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zGm9mFdGuIl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable ending balance">1.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zAXoIT4wMCoi" title="Weighted-average remaining contractual terms (Years), outstanding excerisable">7.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pn3n3_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zCA2Jr4kXkma" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, shares outstanding, exercisable">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

10522995

1.12

P7Y10M17D

60000

0.29

236818

1.81

201001 1.61

10145176

1.09

P7Y9M25D

4784540

1.18

P7Y

60000

30000

0.29

P10Y

12000

0.29

P6Y

0.82

0.0172

225000 300000

2398000

0.30

9. Stock Warrants As of March 31, 2022, the Company has issued warrants to purchase an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220331__us-gaap--StatementEquityComponentsAxis__custom--StockWarrantsMember_zfsxpPCod7vb" title="Warrant to purchase common stock">13,835,768 shares of common stock. The Company’s warrant activity during the three months ended March 31, 2022 is as follows: Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Remaining Contractual Terms (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zeD6nt6dNui8" style="width: 10%; text-align: right" title="Shares outstanding, beginning balance">4,538,479</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z29XOiljVv26" style="width: 10%; text-align: right" title="Weighted-average exercise price, outstanding beginning balance">1.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjUeM2Nj50Db" title="Weighted-average remaining contractual terms (Years), outstanding beginning balance">2.77</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingAggregateIntrinsicValue_iS_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVMwcumdj3s4" style="width: 10%; text-align: right" title="Aggregate intrinsic value shares outstanding beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrLl05sUZ0w" style="text-align: right" title="Shares, Granted">9,297,289</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesGrantedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuttqHepQ5Fj" style="text-align: right" title="Weighted-average exercise price, granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrqcK7Ig6zEc" title="Weighted-Average Remaining Contractual Terms (Years), Outstanding Granted">5.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQTIaFSx7UNd" style="text-align: right" title="Shares, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesExercisedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPR18cTLvKzf" style="text-align: right" title="Weighted-average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPWIso5TKpN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesForfeitedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zI1Ftw3jEEui" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z28oxPS0WbEj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares outstanding, ending balance">13,835,768</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z0tDxHQ0pRuj" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, outstanding ending balance">0.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs73EpFn4wpj" title="Weighted-average remaining contractual terms (Years), outstanding ending balance">4.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingAggregateIntrinsicValue_iE_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAl2Xa5Hu3j7" style="padding-bottom: 1.5pt; text-align: right" title="Aggregate intrinsic value shares outstanding ending">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6tQcW9A1wW" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares exercisable, ending balance">4,538,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z4pQAZMifABl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, outstanding exercisable">0.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightNumberOfSecuritieExercisableWeightedAverageRemainingContractualTerms_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zb1EZzPyajk3" title="Weighted-average remaining contractual terms (Years), outstanding exercisable">4.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ClassOfWarrantOrRightNumberOfSecuritieExercisableAggregateIntrinsicValue_iE_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zux101v8LpB4" style="padding-bottom: 1.5pt; text-align: right" title="Aggregate intrinsic value shares excerisable">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> On March 10, 2022, the Company entered into a securities purchase agreement with certain institutional and accredited investors pursuant to which the investors agreed to purchase <span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20220309__20220310__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrRb3AjMwsX5" title="Common stock and warrants issued for purchase of common stock">18,594,571 shares of the Company’s common stock and warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zSVMC6RnqgZk" title="Common stock available for purchase">9,297,289 shares of common stock in a private placement. The warrants have an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWofXjYFPY1d" title="Warrants exercise price">0.2877 per share for a period of <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220310__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zxBS7J2noZL7" title="Warrants term">five years commencing six months from the closing date of March 11, 2022 (see Note 7). On November 24, 2021, the Company granted John Bello, current Chairman, significant shareholder and former Interim Chief Executive Officer of Reed’s, who is a related party, a <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211124__us-gaap--TypeOfArrangementAxis__custom--SatisfactionSettlementAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--JohnBelloMember_zxkZVnpLSVDh" title="Warrant outstanding term">5-year warrant to purchase <span id="xdx_90E_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20211124__us-gaap--TypeOfArrangementAxis__custom--SatisfactionSettlementAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--JohnBelloMember_z3Ii4Huais14" title="Warrant issued">1,500,000 shares of the Company common stock with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211124__us-gaap--TypeOfArrangementAxis__custom--SatisfactionSettlementAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--JohnBelloMember_zQ9nIcI3xnK3" title="Exercise price">0.46. The fair value of the warrants granted was determined to be $458 and was recorded as a prepaid financing costs. The unamortized balance of prepaid financing costs was $<span id="xdx_90F_eus-gaap--PrepaidExpenseCurrent_iI_pn3n3_c20211231__us-gaap--TypeOfArrangementAxis__custom--SatisfactionSettlementAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--JohnBelloMember_zNhhSINJ0Q08" title="Prepaid financing costs">310 on December 31, 2021. During the three month ended March 31, 2022, the Company amortized $<span id="xdx_90E_eus-gaap--AmortizationOfFinancingCosts_pn3n3_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--SatisfactionSettlementAndReleaseAgreementMember__srt--TitleOfIndividualAxis__custom--JohnBelloMember_zpNszH5tZrG4" title="Amortization of prepaid financing costs">310 of prepaid financing costs to interest expense, leaving no remaining prepaid financing cost balance at March 31, 2022. As of March 31, 2022, the outstanding and exercisable warrants have no aggregate intrinsic value. The aggregate intrinsic value was calculated as the difference between the closing market price as of March 31, 2022, which was $0.30, and the exercise price of the Company’s warrants to purchase common stock.

13835768

Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Remaining Contractual Terms (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zeD6nt6dNui8" style="width: 10%; text-align: right" title="Shares outstanding, beginning balance">4,538,479</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z29XOiljVv26" style="width: 10%; text-align: right" title="Weighted-average exercise price, outstanding beginning balance">1.02</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjUeM2Nj50Db" title="Weighted-average remaining contractual terms (Years), outstanding beginning balance">2.77</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingAggregateIntrinsicValue_iS_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zVMwcumdj3s4" style="width: 10%; text-align: right" title="Aggregate intrinsic value shares outstanding beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrLl05sUZ0w" style="text-align: right" title="Shares, Granted">9,297,289</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesGrantedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zuttqHepQ5Fj" style="text-align: right" title="Weighted-average exercise price, granted">0.29</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTermsGranted_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zrqcK7Ig6zEc" title="Weighted-Average Remaining Contractual Terms (Years), Outstanding Granted">5.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQTIaFSx7UNd" style="text-align: right" title="Shares, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesExercisedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPR18cTLvKzf" style="text-align: right" title="Weighted-average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPWIso5TKpN9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, forfeited or expired">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesForfeitedWeightedAverageExercisePrice_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zI1Ftw3jEEui" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, forfeited">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z28oxPS0WbEj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares outstanding, ending balance">13,835,768</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z0tDxHQ0pRuj" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, outstanding ending balance">0.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs73EpFn4wpj" title="Weighted-average remaining contractual terms (Years), outstanding ending balance">4.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightNumberOfSecuritieOutstandingAggregateIntrinsicValue_iE_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zAl2Xa5Hu3j7" style="padding-bottom: 1.5pt; text-align: right" title="Aggregate intrinsic value shares outstanding ending">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Exercisable at March 31, 2022</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z6tQcW9A1wW" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares exercisable, ending balance">4,538,479</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_985_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z4pQAZMifABl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted-average exercise price, outstanding exercisable">0.53</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_909_ecustom--ClassOfWarrantOrRightNumberOfSecuritieExercisableWeightedAverageRemainingContractualTerms_dtY_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zb1EZzPyajk3" title="Weighted-average remaining contractual terms (Years), outstanding exercisable">4.49</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_984_ecustom--ClassOfWarrantOrRightNumberOfSecuritieExercisableAggregateIntrinsicValue_iE_pn3n3_c20220101__20220331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zux101v8LpB4" style="padding-bottom: 1.5pt; text-align: right" title="Aggregate intrinsic value shares excerisable">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

4538479

1.02 P2Y9M7D

9297289

0.29 P5Y5M12D

13835768

0.53 P4Y5M26D 4538479 0.53 P4Y5M26D

18594571

9297289

0.2877

P5Y

1500000

0.46

458000

310000

0.30

10. Related Party Activities In 2018, the Company completed the sale of its Los Angeles manufacturing plant to California Custom Beverage, LLC (“CCB”), an entity owned by Christopher J. Reed, a related party, and CCB assumed the monthly payments on our lease obligation for the Los Angeles manufacturing plant. Our release from the obligation by the lessor, however, is dependent upon CCB’s deposit of $<span id="xdx_90D_eus-gaap--SecurityDeposit_c20181231__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_pn3n3" title="Deposit of security with lessor">1,200 of security with the lessor. The deposit is secured by Mr. Reed’s pledge of common stock to the lessor and guaranteed personally by Mr. Reed and his wife. As of March 31, 2022, $<span id="xdx_90B_eus-gaap--SecurityDeposit_iI_pn3n3_c20220331__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zEC1lh3CYY6" title="Deposit of security with lessor">800 has been deposited with the lessor and Mr. Reed has placed approximately <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zY2fiM3oe7ia" title="Number of common stock value placed">363,000 pledged shares valued at $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20220101__20220331__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zS7cvcxJQuk3" title="Value of common stock paced">109 that remain in escrow with the lessor. Beginning in 2019, we are to receive a <span id="xdx_900_ecustom--RoyaltyPercentage_iI_pid_dp_uPure_c20191231__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zoRRzeqXOwN8" title="Royalty percentage">5% royalty on CCB’s private label sales to existing customers and a <span id="xdx_900_ecustom--ReferralFeePercentage_iI_pid_dp_uPure_c20191231__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zjHuJUkJtVz7" title="Referral fee percentage">5% referral fee on CCB’s private label sales to referred customers for three years. The royalty agreement terminated December 31, 2021. During the three months ended March 31, 2022 and 2021, the Company recorded royalty revenue from CCB of $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20220101__20220331__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zQgEvjju61y7" title="Revenue">0 and $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_c20210101__20210331__srt--ProductOrServiceAxis__us-gaap--RoyaltyMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_ziUrHIDbCnd5" title="Revenue">3, respectively. At December 31, 2021, the Company had an aggregate receivable balance from CCB of $<span id="xdx_906_ecustom--RoyaltyRevenueReceivable_iI_pn3n3_c20211231__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zRtS6Sz60hsi" title="Royalty revenue receivable">933. During the three months ended March 31, 2022, the Company advanced expenses of $8, leaving an aggregate receivable balance of $<span id="xdx_90F_ecustom--RoyaltyRevenueReceivable_iI_pn3n3_c20220331__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zFWY1WL8NFY4" title="Royalty revenue receivable">941 at March 31, 2022. At March 31, 2022 and December 31, 2021, the Company had accounts payable due to CCB of $<span id="xdx_901_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20220331__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zEVIh8AxZiH" title="Account payble">735 and $<span id="xdx_90D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20211231__srt--TitleOfIndividualAxis__custom--ChrisReedMember__dei--LegalEntityAxis__custom--CaliforniaCustomBeverageLLCMember_zHLS3JgGkDg3" title="Account payble">614, respectively. Lindsay Martin, daughter of a director of the Company, is employed as Vice President of Marketing. Ms. Martin was paid approximately $<span id="xdx_90F_eus-gaap--RelatedPartyCosts_pn3n3_c20220101__20220331__srt--TitleOfIndividualAxis__custom--LindsayMartinMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--VicePresidentMember_zMOt5sZ8i8Qg" title="Amount paid for service">46 and $<span id="xdx_90B_eus-gaap--RelatedPartyCosts_pn3n3_c20210101__20210331__srt--TitleOfIndividualAxis__custom--LindsayMartinMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--VicePresidentMember_zsc3j2v9zPA5" title="Amount paid for service">87, respectively, for her services during the three months ended March 31, 2022 and 2021, respectively.

1200000

800000

363000

109000

0.05 0.05

3000

933000

8000

941000

735000

614000

46000

87000

11. Subsequent Events Subsequent to March 31, 2022, the Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220401__20220516__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWir0Fdu1rF6" title="Number of restricted stock issued">100,430 shares of common stock on the vesting of restricted shares. On May 9, 2022, the Company entered into a note purchase agreement and agreed to issue $<span id="xdx_90D_eus-gaap--SecuredDebt_iI_pn3n3_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z53OeXCo5Xwj" title="Secured debt">11,250 of secured convertible promissory notes (the “Notes”). The net proceeds from the issuance of the Notes, after deducting placement agent fees and other offering expenses, was approximately $<span id="xdx_906_ecustom--DebtAfterDeductingPlacementAgentFeesAndOtherOfferingExpenses_iI_pn3n3_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zAy726th8gPh" title="Notes after deducting placement agent fees and other offering expenses">10,013. The Notes will mature on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z1ZiKWso9Pmi" title="Debt maturity date">May 9, 2025, bear interest at a rate of <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zcYRnaZPNBJ6" title="Debt interest rate">10% per annum, and are secured by substantially all of the Company’s assets (including all of its intellectual property) and are subject to a collateral sharing agreement with ACS, the Company’s existing secured lender (see Note 5). The Notes also have an amortization feature beginning in August 2022, which, if elected by a majority of holders, would require the Company to make monthly payments of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20220508__20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z5IWbAH856Oe" title="Monthly payment">200 of principal and interest in cash or in shares of common stock. The initial conversion rate of the Notes is <span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_z6kbwqlpplXb" title="Debt conversion per share">4.1503 shares of the Company’s common stock per one dollar of principal converted, subject to customary anti-dilution adjustments. Upon conversion, holders of the Note are entitled to receive an interest make-whole payment, as defined, which is payable, at the Company’s election, in cash or in shares of common stock valued at a <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20220509__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--NotePurchaseAgreementMember_zuXEytwkppv4" title="Debt interest rate">10% discount to the 5-day volume-weighted average price. The Company’s ability to settle conversions and make amortization and interest make-whole payments using shares of the Company’s common stock is subject to certain limitations set forth in the Notes. The Company entered into a registration rights agreement with the holders, pursuant to which the Company agreed to register for resale shares issuable under the Notes within 45 days of the closing of Notes. The Company is currently in the process of determining its accounting for the Notes.

100430

11250000

10013000

2025-05-09

0.10

200000

4.1503

0.10